Amanote Research
Register
Sign In
Prm29 - Comparing Opthalmology Treatments via the Integration of Ipd and Aggregate-Level Data: Which Matching Adjusted Indirect Comparison (Maic) Approach Is Best?
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2153
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
J Alsop
Publisher
Elsevier BV
Related search
Prm239 - Does Matching Adjusted Indirect Comparison (Maic) Work? Results From a Simulation Study
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Alternative Weighting Approaches for Matching Adjusted Indirect Comparisons (Maic)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Matching Adjusted Indirect Comparison (MAIC) Analysis for Ponatinib vs Bosutinib in Third-Line Chronic Phase Chronic Myeloid Leukemia (CP-CML)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Prm236 - Calibrating Matching Adjusted Indirect Comparison Estimate to Real-World Population
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Comparative Effectiveness of Treatments for Relapsed or Refractory Mantle Cell Lymphoma (R/R McL), Using Matching Adjusted Indirect Comparison
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Matching-Adjusted Indirect Comparison of Benralizumab Versus Interleukin-5 Inhibitors: Systematic Review
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Matching Adjusted Indirect Comparison of Sunitinib and Everolimus for the Treatment of Pancreatic Neuroendocrine Tumours (PNETS)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Matching-Adjusted Indirect Comparison: Secukinumab Versus Infliximab in Biologic-Naive Patients With Psoriatic Arthritis
Journal of Comparative Effectiveness Research
Health Policy
SAT0480 Comparative Effectiveness of Secukinumab and Infliximab in Psoriatic Arthritis Assessed by Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data
